DAMORA THERAPEUTICS, INC. Share-based Payment Arrangement, Expense
DAMORA THERAPEUTICS, INC. (DMRA) reported Share-based Payment Arrangement, Expense of $10.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $10.69M, a 6113.37% increase year-over-year.
- DAMORA THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $8.12M, a 4435.20% increase year-over-year.
- DAMORA THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $483.00K, a 56.82% increase year-over-year.
- DAMORA THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $164.00K, a 75.92% decline year-over-year.
- DAMORA THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2025 was $998.00K, a 69.19% decline from fiscal 2024.
- DAMORA THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2024 was $3.24M, a 40.32% decline from fiscal 2023.
- DAMORA THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2023 was $5.43M, a 2.58% decline from fiscal 2022.
- DAMORA THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2022 was $5.57M, a 24.35% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.69M 10-Q · filed 2026-08-10 | $18.80M 10-Q · filed 2026-08-10 | $19.29M derived: sum of 3 quarters · filed 2026-08-10 | $19.45M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $8.12M 10-Q · filed 2026-05-12 | $8.60M derived: sum of 2 quarters · filed 2026-05-12 | $8.77M derived: sum of 3 quarters · filed 2026-05-12 | $8.94M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $483.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $647.00K derived: sum of 2 quarters · filed 2026-03-19 | $819.00K derived: sum of 3 quarters · filed 2026-08-10 | $998.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $164.00K 10-Q · filed 2025-11-06 | $336.00K derived: sum of 2 quarters · filed 2026-08-10 | $515.00K 10-Q · filed 2025-11-06 | $823.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $172.00K 10-Q · filed 2026-08-10 | $351.00K 10-Q · filed 2026-08-10 | $659.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.34M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $179.00K 10-Q · filed 2026-05-12 | $487.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.17M derived: sum of 3 quarters · filed 2026-05-12 | $2.06M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $308.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $989.00K derived: sum of 2 quarters · filed 2026-03-19 | $1.88M derived: sum of 3 quarters · filed 2026-03-19 | $3.24M 10-K · filed 2026-03-19 |
| 2024-09-30 | $681.00K 10-Q · filed 2025-11-06 | $1.57M derived: sum of 2 quarters · filed 2025-11-06 | $2.93M 10-Q · filed 2025-11-06 | $4.02M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $891.00K 10-Q · filed 2025-08-05 | $2.25M 10-Q · filed 2025-08-05 | $3.34M derived: sum of 3 quarters · filed 2025-08-05 | $4.80M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $1.36M 10-Q · filed 2025-05-08 | $2.45M derived: sum of 2 quarters · filed 2025-05-08 | $3.91M derived: sum of 3 quarters · filed 2025-05-08 | $5.35M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $2.55M derived: sum of 2 quarters · filed 2025-03-19 | $3.99M derived: sum of 3 quarters · filed 2025-03-19 | $5.43M 10-K · filed 2025-03-19 |
| 2023-09-30 | $1.46M 10-Q · filed 2024-11-01 | $2.90M derived: sum of 2 quarters · filed 2024-11-01 | $4.34M 10-Q · filed 2024-11-01 | $5.69M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $1.44M 10-Q · filed 2024-08-12 | $2.87M 10-Q · filed 2024-08-12 | $4.22M derived: sum of 3 quarters · filed 2024-08-12 | $5.62M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $1.43M 10-Q · filed 2024-04-29 | $2.78M derived: sum of 2 quarters · filed 2024-04-29 | $4.18M derived: sum of 3 quarters · filed 2024-04-29 | $5.60M derived: sum of 4 quarters · filed 2024-04-29 |
| 2022-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $2.75M derived: sum of 2 quarters · filed 2024-03-08 | $4.17M derived: sum of 3 quarters · filed 2024-03-08 | $5.57M 10-K · filed 2024-03-08 |
| 2022-09-30 | $1.40M 10-Q · filed 2023-11-06 | $2.82M derived: sum of 2 quarters · filed 2023-11-06 | $4.22M 10-Q · filed 2023-11-06 | $5.46M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $1.42M 10-Q · filed 2023-07-31 | $2.82M 10-Q · filed 2023-07-31 | $4.07M derived: sum of 3 quarters · filed 2023-07-31 | $5.29M derived: sum of 4 quarters · filed 2023-07-31 |
| 2022-03-31 | $1.40M 10-Q · filed 2023-04-28 | $2.65M derived: sum of 2 quarters · filed 2023-04-28 | $3.87M derived: sum of 3 quarters · filed 2023-04-28 | $4.85M derived: sum of 4 quarters · filed 2023-04-28 |
| 2021-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $2.46M derived: sum of 2 quarters · filed 2023-03-09 | $3.45M derived: sum of 3 quarters · filed 2023-03-09 | $4.48M 10-K · filed 2023-03-09 |
| 2021-09-30 | $1.22M 10-Q · filed 2022-11-08 | $2.21M derived: sum of 2 quarters · filed 2022-11-08 | $3.24M 10-Q · filed 2022-11-08 | $3.74M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $987.00K 10-Q · filed 2022-07-29 | $2.02M 10-Q · filed 2022-07-29 | $2.52M derived: sum of 3 quarters · filed 2022-07-29 | $2.65M derived: sum of 4 quarters · filed 2022-07-29 |
| 2021-03-31 | $1.03M 10-Q · filed 2022-04-29 | $1.53M derived: sum of 2 quarters · filed 2022-04-29 | $1.67M derived: sum of 3 quarters · filed 2022-04-29 | $2.04M derived: sum of 4 quarters · filed 2022-04-29 |
| 2020-12-31 | $502.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $636.00K derived: sum of 2 quarters · filed 2022-02-17 | $1.01M derived: sum of 3 quarters · filed 2022-02-17 | $1.01M 10-K · filed 2022-02-17 |
| 2020-09-30 | $134.00K 10-Q · filed 2021-11-04 | $508.00K derived: sum of 2 quarters · filed 2021-11-04 | $507.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $374.00K 10-Q · filed 2021-08-05 | $374.00K 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |